Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso New Pharmaceuticals products deliver strong growth – headwinds in Chinao Consumer Health continues to growEBITDA before special items: 4.471 billion euros (minus 14.9 percent)o Glyphosate and inflation weigh on earningso Pharmaceuticals maintains high R&D investmentCore earnings per share at 2.95 euros (minus 16.4 percent)Net income at 2.178 billion eurosFree cash flow at minus 4.102 billion eurosGroup outlook confirmed – target attainment at lower end of guidance Leverkusen…
Read More
